Jantina C de Groot1, Eric N H van Roon2, Huib Storm3, Nic J G M Veeger4, Aeilko H Zwinderman5, Pieter S Hiemstra6, Elisabeth H D Bel7, Anneke ten Brinke8. 1. Department of Respiratory Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands. Electronic address: christa_de_groot@yahoo.com. 2. Department of Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, The Netherlands; Department of Hospital Pharmacy, Medical Centre Leeuwarden, Leeuwarden, The Netherlands. 3. Department of Clinical Chemistry, Medical Centre Leeuwarden, Leeuwarden, The Netherlands. 4. Department of Clinical Epidemiology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands. 5. Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam Medical Centre, Amsterdam, The Netherlands. 6. Department of Pulmonology, Leiden University Medical Centre, Leiden, The Netherlands. 7. Department of Respiratory Medicine, Amsterdam Medical Centre, Amsterdam, The Netherlands. 8. Department of Respiratory Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
Abstract
BACKGROUND:Low levels of vitamin D are associated with asthma severity, airway remodeling, and exacerbation rate increase, especially in nonatopic asthma. Reduced steroid responsiveness or impaired antimicrobial defense might be underlying mechanisms. OBJECTIVE: We sought to evaluate the effect of vitamin D supplementation on eosinophilic and neutrophilic airway inflammation in patients with nonatopic asthma. METHODS: In a double-blind, randomized, placebo-controlled trial, we investigated the effect of long-acting vitamin D3 (400,000 IU) on sputum neutrophils and eosinophils in 44 patients with nonatopic asthma with neutrophilic (≥53%) and/or eosinophilic (≥3%) airway inflammation. Sputum induction was performed at baseline and after 9 weeks. Other measurements included questionnaires, blood samples, and pulmonary function. RESULTS: Treatment with vitamin D did not significantly affect sputum neutrophils or eosinophils compared with treatment with placebo in the total group. Regarding sputum eosinophils, the effect of vitamin D appeared to be dependent on baseline sputum eosinophil levels (interaction P = .015). In patients with eosinophil levels of 26.2% or more (median in patients with sputum eosinophilia, >3%), eosinophils decreased from a median of 41.0% to 11.8% after vitamin D treatment as compared with an increase from 51.8% to 63.3% in patients receiving placebo (P = .034). Vitamin D treatment also resulted in slightly better Asthma Control Questionnaire scores (P = .08). CONCLUSIONS:Vitamin D supplementation reduced eosinophilic airway inflammation in patients with nonatopic asthma with severe eosinophilic airway inflammation, but did not affect sputum neutrophils. Also, a small effect on asthma control was observed. These findings suggest that vitamin D might have potential as an add-on treatment option in eosinophilic asthma.
RCT Entities:
BACKGROUND: Low levels of vitamin D are associated with asthma severity, airway remodeling, and exacerbation rate increase, especially in nonatopic asthma. Reduced steroid responsiveness or impaired antimicrobial defense might be underlying mechanisms. OBJECTIVE: We sought to evaluate the effect of vitamin D supplementation on eosinophilic and neutrophilic airway inflammation in patients with nonatopic asthma. METHODS: In a double-blind, randomized, placebo-controlled trial, we investigated the effect of long-acting vitamin D3 (400,000 IU) on sputum neutrophils and eosinophils in 44 patients with nonatopic asthma with neutrophilic (≥53%) and/or eosinophilic (≥3%) airway inflammation. Sputum induction was performed at baseline and after 9 weeks. Other measurements included questionnaires, blood samples, and pulmonary function. RESULTS: Treatment with vitamin D did not significantly affect sputum neutrophils or eosinophils compared with treatment with placebo in the total group. Regarding sputum eosinophils, the effect of vitamin D appeared to be dependent on baseline sputum eosinophil levels (interaction P = .015). In patients with eosinophil levels of 26.2% or more (median in patients with sputum eosinophilia, >3%), eosinophils decreased from a median of 41.0% to 11.8% after vitamin D treatment as compared with an increase from 51.8% to 63.3% in patients receiving placebo (P = .034). Vitamin D treatment also resulted in slightly better Asthma Control Questionnaire scores (P = .08). CONCLUSIONS:Vitamin D supplementation reduced eosinophilic airway inflammation in patients with nonatopic asthma with severe eosinophilic airway inflammation, but did not affect sputum neutrophils. Also, a small effect on asthma control was observed. These findings suggest that vitamin D might have potential as an add-on treatment option in eosinophilic asthma.
Authors: Adrian R Martineau; Christopher J Cates; Mitsuyoshi Urashima; Megan Jensen; Alex P Griffiths; Ulugbek Nurmatov; Aziz Sheikh; Chris J Griffiths Journal: Cochrane Database Syst Rev Date: 2016-09-05
Authors: P Haag; H Sharma; M Rauh; T Zimmermann; T Vuorinen; N G Papadopoulos; S T Weiss; S Finotto Journal: Clin Exp Immunol Date: 2018-05-31 Impact factor: 4.330
Authors: Mohammad J Alkhatatbeh; Haneen S Almomani; Khalid K Abdul-Razzak; Shaher Samrah Journal: NPJ Prim Care Respir Med Date: 2021-05-14 Impact factor: 2.871
Authors: Balázs Odler; István Ivancsó; Vivien Somogyi; Kálmán Benke; Lilla Tamási; Gabriella Gálffy; Balázs Szalay; Veronika Müller Journal: Int J Chron Obstruct Pulmon Dis Date: 2015-09-24
Authors: Andrea Ticinesi; Tiziana Meschi; Fulvio Lauretani; Giovanna Felis; Fabrizio Franchi; Carlo Pedrolli; Michela Barichella; Giuseppe Benati; Sergio Di Nuzzo; Gian Paolo Ceda; Marcello Maggio Journal: Nutrients Date: 2016-03-29 Impact factor: 5.717